Yield10 Bioscience Announces Key Advancements in the Development of Herbicide Tolerant Camelina Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market
-Second field trial confirms Camelina tolerance to over-the-top herbicide application
-Greenhouse studies support proof-of-concept for stacked herbicide traits in Camelina
-Yield10 filed RSR under USDA-APHIS’s SECURE Rule for herbicide tolerant Camelina
Control of broadleaf weeds is essential for the adoption and success of commercial crops in
In the 2022 spring growing season, Yield10 demonstrated for the first time that its HT spring Camelina lines were tolerant to application of a commonly used broadleaf herbicide. In the fall 2022/2023 growing season, Yield10 retested its lead commercial candidate HT spring Camelina lines in field trials in the Southern US and the successful results were replicated. These HT spring Camelina lines were also tolerant to the application of a grassy weed control product.
Further seed scale-up and field testing of the Company’s lead commercial HT spring Camelina lines are expected to continue in 2023. A request for Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (BRS) for herbicide tolerant Camelina under the SECURE Rule was filed by Yield10 in 2022, and a response from the agency is pending.
“Our team has made substantial progress developing elite herbicide tolerant spring and winter Camelina varieties,” said
A summary of recent advancements in Yield10’s development of elite herbicide tolerant spring and winter Camelina varieties:
Development of commercial quality herbicide tolerant E3902 spring Camelina. Yield10 confirmed tolerance to over-the-top spray application of a commonly used broad leaf herbicide in a second field trial of E3902 HT spring Camelina conducted at two sites this winter in contra-season. Broad-spectrum herbicides have been used to protect seed yield by controlling broadleaf weeds during commercial crop production for over 30 years. In this field trial, Yield10 also demonstrated that its E3902 HT spring Camelina is tolerant to application of Clethodim, a herbicide used to manage grassy weeds. In 2023, Yield10 plans to conduct further seed scale-up activities and field tests of its lead herbicide tolerant E3902 spring Camelina lines.
Development of stacked herbicide tolerant E3902 spring Camelina. Yield10 researchers have developed multiple E3902 spring Camelina lines with “stacked” herbicide tolerance traits. In recently completed greenhouse studies, these E3902 Camelina lines were tolerant to a broad leaf herbicide application as well as to soil residues of group 2 herbicides (“IMI”/imidazolinones and “SU”/sulfonlyurea), which are commonly used to manage weeds in cereal and other crop rotations. Based on achieving proof-of-concept for stacked herbicide tolerant Camelina, Yield10 plans to conduct the first field tests of stacked herbicide tolerant E3902 spring Camelina lines in spring 2023.
Development of stacked herbicide tolerant winter Camelina. Yield10 researchers have developed candidate broadleaf herbicide tolerant winter Camelina in WDH2 and WDH3 germplasm. In recently completed greenhouse studies these candidate winter Camelina lines demonstrated tolerance to spray application of commercial levels of a commonly used broadleaf herbicide. These events are on-track for field testing in winter 2023/2024. Yield10 is also developing “stacked” herbicide tolerance traits in its winter Camelina lines with the goal of conducting its first field tests in winter 2023/2024.
Regulatory process for herbicide tolerant Camelina is underway in the
About the SECURE Rule
The SECURE Rule was published on
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, expectations related to research and development activities, the expected regulatory path for its traits, the reproducibility of data from greenhouse and field tests, the start and timing of completion of field tests and seed scale-up activities, commercial launch plans, and the overall progress of
Managing Director, CORE IR
Source: Yield10 Bioscience, Inc.